BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37600808)

  • 1. Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.
    Vanselow S; Wahn V; Schuetz C
    Front Immunol; 2023; 14():1208567. PubMed ID: 37600808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
    Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
    J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
    Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
    Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future Directions in the Diagnosis and Treatment of APDS and IEI: a Survey of German IEI Centers.
    Vanselow S; Hanitsch L; Hauck F; Körholz J; Maccari ME; Meinhardt A; Sogkas G; Schuetz C; Grimbacher B
    Front Immunol; 2023; 14():1279652. PubMed ID: 37868971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of mortality and survival rates for APDS.
    Hanson J; Bonnen PE
    Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
    Redenbaugh V; Coulter T
    Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
    Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
    Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
    Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
    Front Immunol; 2018; 9():543. PubMed ID: 29599784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment.
    Lougaris V; Piane FL; Cancrini C; Conti F; Tommasini A; Badolato R; Trizzino A; Zecca M; De Rosa A; Barzaghi F; Pignata C
    Ital J Pediatr; 2024 May; 50(1):103. PubMed ID: 38769568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
    Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
    Yang X; Xi R; Bai J; Pan Y
    Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment of Activated PI3Kδ Syndrome.
    Coulter TI; Cant AJ
    Front Immunol; 2018; 9():2043. PubMed ID: 30245694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients.
    Tessarin G; Rossi S; Baronio M; Gazzurelli L; Colpani M; Benvenuto A; Zunica F; Cardinale F; Martire B; Brescia L; Costagliola G; Luti L; Casazza G; Menconi MC; Saettini F; Palumbo L; Girelli MF; Badolato R; Lanzi G; Chiarini M; Moratto D; Meini A; Giliani S; Bondioni MP; Plebani A; Lougaris V
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33080915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.